[
  {
    "ts": "2026-02-12T01:22:00+00:00",
    "headline": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
    "summary": "SANTA CLARA, Calif., February 12, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
    "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f1e04c13-ee6a-337d-bb05-8f200b17e962",
      "content": {
        "id": "f1e04c13-ee6a-337d-bb05-8f200b17e962",
        "contentType": "STORY",
        "title": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
        "description": "",
        "summary": "SANTA CLARA, Calif., February 12, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
        "pubDate": "2026-02-12T01:22:00Z",
        "displayTime": "2026-02-12T01:22:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad",
          "originalWidth": 1000,
          "originalHeight": 404,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PQWewlSpOjq3LBzkeZ9umg--~B/aD00MDQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad.cf.webp",
              "width": 1000,
              "height": 404,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W0iu6UMRdyYDW2qH3YUL1w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "A"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T01:25:00+00:00",
    "headline": "Improved Pharma Expands Pharmaceutical Development Services with New Automated Dissolution Capabilities",
    "summary": "Improved Pharma, a leader in pharmaceutical research and solid-state chemistry, is pleased to announce a significant upgrade to its analytical capabilities with the installation of a fully automated dissolution system. The new equipment, featuring the Agilent 708-DS dissolution apparatus paired with the 850-DS autosampler, enhances the company's ability to provide high-resolution, information-rich data for complex drug products.",
    "url": "https://finance.yahoo.com/news/improved-pharma-expands-pharmaceutical-development-012500704.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "00271de3-3ed1-3869-bee8-b8d5a65a8b0d",
      "content": {
        "id": "00271de3-3ed1-3869-bee8-b8d5a65a8b0d",
        "contentType": "STORY",
        "title": "Improved Pharma Expands Pharmaceutical Development Services with New Automated Dissolution Capabilities",
        "description": "",
        "summary": "Improved Pharma, a leader in pharmaceutical research and solid-state chemistry, is pleased to announce a significant upgrade to its analytical capabilities with the installation of a fully automated dissolution system. The new equipment, featuring the Agilent 708-DS dissolution apparatus paired with the 850-DS autosampler, enhances the company's ability to provide high-resolution, information-rich data for complex drug products.",
        "pubDate": "2026-02-12T01:25:00Z",
        "displayTime": "2026-02-12T01:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/dc0bbb9e58d13e13512620c6b7d3753c",
          "originalWidth": 400,
          "originalHeight": 100,
          "caption": "Improved Pharma (PRNewsfoto/Improved Pharma)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/en077jD_LBhnFH9DXUN7ug--~B/aD0xMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dc0bbb9e58d13e13512620c6b7d3753c.cf.webp",
              "width": 400,
              "height": 100,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y2yyDAU3ghpjVc5tNa6KjQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dc0bbb9e58d13e13512620c6b7d3753c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/improved-pharma-expands-pharmaceutical-development-012500704.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/improved-pharma-expands-pharmaceutical-development-012500704.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "A"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T22:35:01+00:00",
    "headline": "Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates",
    "summary": "Bio-Rad (BIO) delivered earnings and revenue surprises of -2.34% and +0.01%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finance.yahoo.com/news/bio-rad-laboratories-bio-q4-223501046.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "aa0b519f-48fc-3193-8a89-a6183297e932",
      "content": {
        "id": "aa0b519f-48fc-3193-8a89-a6183297e932",
        "contentType": "STORY",
        "title": "Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates",
        "description": "",
        "summary": "Bio-Rad (BIO) delivered earnings and revenue surprises of -2.34% and +0.01%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
        "pubDate": "2026-02-12T22:35:01Z",
        "displayTime": "2026-02-12T22:35:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uV6mPOIlsfK8Kl7nmlunJw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sc4z8_.3guA7NR27rd8O3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bio-rad-laboratories-bio-q4-223501046.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bio-rad-laboratories-bio-q4-223501046.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIO"
            },
            {
              "symbol": "A"
            },
            {
              "symbol": "BIO-B"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]